| 1.51 0.02 (1.34%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.94  |
1-year : | 2.11 |
| Resists | First : | 1.66 |
Second : | 1.8 |
| Pivot price | 1.54  |
|||
| Supports | First : | 1.44 |
Second : | 1.19 |
| MAs | MA(5) : | 1.49 |
MA(20) : | 1.57 |
| MA(100) : | 1.54 |
MA(250) : | 2.32 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 21.3 |
D(3) : | 19.3 |
| RSI | RSI(14): 47.3 |
|||
| 52-week | High : | 6.23 | Low : | 1.15 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RMTI ] has closed above bottom band by 36.2%. Bollinger Bands are 27.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.56 - 1.57 | 1.57 - 1.58 |
| Low: | 1.43 - 1.44 | 1.44 - 1.45 |
| Close: | 1.5 - 1.51 | 1.51 - 1.52 |
Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
Wed, 17 Apr 2024
Rockwell Medical Continues to Expand its Distribution Capabilities in Western United States - Business Wire
Tue, 16 Apr 2024
Rockwell Medical to Release First Quarter 2024 Results on Tuesday, May 14, 2024 - Business Wire
Thu, 04 Apr 2024
Rockwell Medical stock gains on sales deals (NASDAQ:RMTI) - Seeking Alpha
Thu, 04 Apr 2024
Rockwell Medical Expands Global Distribution in the Dominican Republic and Bermuda - Business Wire
Fri, 22 Mar 2024
Rockwell Medical, Inc. (NASDAQ:RMTI) Q4 2023 Earnings Call Transcript - Yahoo Finance
Thu, 21 Mar 2024
Rockwell Medical, Inc. (RMTI) Q4 2023 Earnings Call Transcript - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 29 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 17.4 (%) |
| Shares Short | 676 (K) |
| Shares Short P.Month | 629 (K) |
| EPS | -0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.73 |
| Profit Margin | -10.1 % |
| Operating Margin | -2.5 % |
| Return on Assets (ttm) | -8.5 % |
| Return on Equity (ttm) | -47.7 % |
| Qtrly Rev. Growth | 14.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 2.84 |
| EBITDA (p.s.) | -0.18 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -4.09 |
| PEG Ratio | -0.4 |
| Price to Book value | 2.06 |
| Price to Sales | 0.53 |
| Price to Cash Flow | -4.72 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|